Want to see GRI full AI Analyst Report?
GRI Stock Chart & Stats
$1.91
-$0.05(-3.45%)
At close: 4:00 PM EDT
$1.91
-$0.05(-3.45%)
Day’s Range― - ―
52-Week Range$1.36 - $64.09
Previous CloseN/A
Volume6.87K
Average Volume (3M)404.06K
Market Cap
$3.67M
Enterprise Value-$7.71M
Total Cash (Recent Filing)$10.95M
Total Debt (Recent Filing)$44.00K
Price to Earnings (P/E)―
Beta2.56
Next Earnings
May 20, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-80.38
Shares Outstanding2,186,115
10 Day Avg. Volume46,097
30 Day Avg. Volume404,060
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap-2.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.85K
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$27.00Price Target Upside1313.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 2a Biomarker And Tolerability DataPositive Phase 2a translational results strengthen the evidence base for GRI-0621 and support progression toward pivotal testing. The reported biomarker consistency, symptom signals, and favorable tolerability may improve the candidate’s clinical differentiation if confirmed in larger studies.
Orphan Drug Designation Supports Potential IPF ExclusivityOrphan Drug Designation improves the potential commercial profile of GRI-0621 by offering seven years of U.S. exclusivity if the drug is approved. That protection could support future market positioning and provide a longer runway to recover development investment.
Low Leverage And Improved Equity BaseMinimal debt reduces solvency pressure and limits interest-related demands on a company still funding clinical development. The stronger equity base also indicates recapitalization and provides greater balance-sheet stability, although it does not yet replace the need for external financing.
Bears Say
Pre-commercial Business With Zero RevenueGRI Bio remains pre-commercial, with no product revenue to offset research and development spending. Until a candidate reaches approval and commercialization, the company lacks recurring operating income, making financial progress dependent on clinical execution and access to funding.
Persistent And Sizable Net LossesSizable losses across successive periods show that development costs continue to outweigh any operating income and that profitability is not yet visible. Persistent negative returns reduce financial flexibility and increase the capital required to advance the pipeline through later-stage trials.
Deepening Cash Burn Increases Financing DependenceThe worsening cash outflow indicates that operations consume substantial funding while the company remains pre-revenue. Continued negative free cash flow will likely require additional external capital to sustain research and clinical programs, creating financing dependence and potential dilution pressure.
GRI Bio News
GRI FAQ
What was GRI Bio’s price range in the past 12 months?
GRI Bio lowest stock price was $1.36 and its highest was $64.09 in the past 12 months.
What is GRI Bio’s market cap?
GRI Bio’s market cap is $3.67M.
When is GRI Bio’s upcoming earnings report date?
GRI Bio’s upcoming earnings report date is May 20, 2027 which is in 222 days.
How were GRI Bio’s earnings last quarter?
GRI Bio released its earnings results on Aug 19, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$1.195 by $0.285.
Is GRI Bio overvalued?
According to Wall Street analysts GRI Bio’s price is currently Undervalued.
Does GRI Bio pay dividends?
GRI Bio does not currently pay dividends.
What is GRI Bio’s EPS estimate?
GRI Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GRI Bio have?
GRI Bio has 2,186,115 shares outstanding.
What happened to GRI Bio’s price movement after its last earnings report?
GRI Bio reported an EPS of -$0.91 in its last earnings report, beating expectations of -$1.195. Following the earnings report the stock price went up 1.17%.
Which hedge fund is a major shareholder of GRI Bio?
Currently, no hedge funds are holding shares in GRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$27.00
▲(1313.61% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.36% Mutual Funds
― Other Institutional Investors
98.66% Public Companies and
Individual Investors